Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

MediciNova Inc (NASDAQ:MNOV)

6.55
Delayed Data
As of Aug 23
 +0.08 / +1.24%
Today’s Change
2.62
Today|||52-Week Range
10.16
+84.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$225.8M

Company Description

MediciNova, Inc. operates as a biopharmaceutical company with interest in acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. The company's development pipeline consists of product development programs which have been in clinical development for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorder, preterm labor and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in San Diego, CA.

Contact Information

MediciNova, Inc.
4275 Executive Square
La Jolla California 92037
P:(858) 373-1500
Investor Relations:

Employees

Shareholders

Other institutional5.05%
Mutual fund holders13.17%
Individual stakeholders10.90%

Top Executives

Yuichi IwakiPresident, Chief Executive Officer & Director
Ryan J. SelhornChief Financial Officer
Kazuko MatsudaChief Medical Officer
Masatsune OkajimaVice President & Head-Japanese Office
Geoffrey G. O'BrienVice President & Head-Investor Relations